drugset / Trial / NCT05265988

Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib

NCT05265988 ↗

Phase 2 Completed 32 enrolled Alfredo Berruti
NaSingle-groupOpen-labelTreatment

Summary

Multiparametric assesment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study

Timeline

Start
2021-11-29
Primary completion
2024-06-29
Completion
2024-06-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabozantinib Small molecule 40 mg —

Indications